Vivos Inc. (OTCQB RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision
Industry development with potential relevance for veterinary professionals, companion animal care, and animal health stakeholders.
Digital tools are becoming increasingly important across veterinary medicine, from clinical workflows to client communication and practice operations.
According to the announcement, Vivos Inc. (OTCQB RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide. The development is relevant because it reflects how animal health companies, service providers, and technology platforms are responding to changing expectations in veterinary care.
What Was Announced
Kennewick, WA, July 06, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy ™ (PRnT) for the treatment of cancerous tumors, is pleased to announce that it has received approval from the U.S. Food and Drug Administration (FDA) for its Feasibility Investigational Device Exemption (IDE) application. This approval allows the Company to begin the US based first-in-human feasibility study using RadioGel ® , an innovative yttrium-90-based injectable hydrogel for the targeted treatment of cancerous tumors.
Why This Matters for Veterinary Professionals
For veterinary professionals, technology announcements matter when they affect efficiency, access to care, diagnostics, reimbursement, or the daily workflow of the clinic.
At the practice level, the most relevant question is whether the development can reduce administrative friction, improve access to information, or support more consistent communication between veterinary teams and clients.
Industry Perspective
The animal health industry continues to move toward more connected, data-driven services for veterinary practices and pet owners.
While individual announcements should be interpreted in the context of their source, they can help veterinary professionals monitor where investment, innovation, and market attention are moving across the animal health sector.
Original announcement: GlobeNewswire Veterinary Search — https://www.globenewswire.com/news-release/2026/07/06/3322418/0/en/vivos-inc-otcqb-rdgl-receives-u-s-fda-approval-for-investigational-device-exemption-ide-to-initiate-human-clinical-feasibility-study-for-radiogel-precision-radionuclide-therapy.html
Comments
Related Articles
More news
Copyright © 2026 - All Rights Reserved
ISSN 2768-198X
List
Add
Please enter a comment